Glioblastoma multiforme (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common and most aggressive cancer that begins within the brain. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li Fraumeni syndrome and previous radiation therapy. Typically, treatment involves surgery after which chemotherapy and radiation therapy is used. The medication temozolomide is frequently used as part of chemotherapy, whereas high dose steroids are used to help reduce swelling and decrease symptoms.
The global Glioblastoma multiforme drugs market segmentation is based on drug types (Bevacizumab, Temozolomide, Carmustine). The global Glioblastoma multiforme drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global Glioblastoma multiforme drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global Glioblastoma multiforme drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
The Temozolomide segment accounted for the largest share of the global Glioblastoma multiforme drugs market in 2015, while Bevacizumab (Avastin) was the fastest growing segment during the forecast period 2016-2020. Rising geriatric population, increasing awareness campaigns and introduction of new technolgies are driving the global Glioblastoma multiforme drugs market. North America accounted for the largest market share, followed by Asia Pacific region.